Company profile

Lixte Biotechnology Holdings, Inc.

Pipeline1 asset

LB-100LB-100 / Protein Phosphatase 2A (PP2A) / Small Molecule / Oncology
Ovarian Clear Cell CarcinomaPhase 2ActiveUnited StatesMetastatic Colon CancerPhase 1bActiveGlobalAdvanced Soft Tissue SarcomaPhase 1/2PausedEurope

Latest news8 items

May 14, 2026

LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update

Presentation / Abstract

Apr 13, 2026

Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference

Interim Data

Mar 31, 2026

LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year

Feb 18, 2026

LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary

Jan 21, 2026

DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE

Jan 20, 2026

LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29

Dec 23, 2025

LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial

Dec 18, 2025

Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

Lixte Biotechnology Holdings, Inc. • Endpoint Arena